Showing 4811-4820 of 21478 results for "".
- Attovia Previews ATTO-1310 and ATTO-2306 Dermatology Postershttps://reachmd.com/news/attovia-atto-1310-atto-2306-posters/2488644/Key Takeaways Attovia plans to present interim ATTO-1310 data in patients with high-itch atopic dermatitis or chronic pruritus at the Fall Clinical Dermatology Conference. The ATTO-1310 study is a single-dose, randomized, double-blind, and placebo-controlled trial.</
- FDA Approves Remibrutinib as First Treatment for Symptomatic Dermographismhttps://reachmd.com/news/fda-approves-remibrutinib-as-first-treatment-for-symptomatic-dermographism/2488642/The FDA has approved Rhapsido (remibrutinib; Novartis) for adults with symptomatic dermographism (SD) whose disease is inadequately controlled with H1 antihistamines, according to an October 7 announcement from Novartis. The approval makes remibrutinib the first FDA-approved treatment spec
- Earlier-Onset Atopic Dermatitis Linked With Cow’s Milk Sensitization: Studyhttps://reachmd.com/news/earlier-onset-atopic-dermatitis-linked-with-cows-milk-sensitization-study/2488641/Egg and cow’s milk were the most common food allergens identified by skin prick testing among infants with atopic dermatitis (AD) in a 17-year retrospective study from Iran, although the investigators cautioned that testing alone cannot establish clinically confirmed food allergy. Publishe
- Xeligekimab in Plaque Psoriasis: Regional and DLQI Gainshttps://reachmd.com/news/xeligekimab-in-plaque-psoriasis-regional-and-dlqi-gains/2488638/Key Takeaways In Chinese adults with moderate-to-severe plaque psoriasis in a phase 3 trial, xeligekimab was associated with high week-12 ideal and acceptable target attainment that remained high through week 52. Xeligekimab produced markedly greater week-4 PASI comp
- Sun Pharma Establishes $2.5 Million Dermatology Professorship at Mount Sinaihttps://reachmd.com/news/sun-pharma-establishes-25-million-dermatology-professorship-at-mount-sinai/2488636/Sun Pharma has established an endowed dermatology professorship at the Icahn School of Medicine at Mount Sinai, naming longtime psoriasis researcher and academic dermatologist Mark G. Lebwohl, MD, as its inaugural holder. Supported by a $2.5 million endowment from Sun Pharma, the Sun Profe
- Zasocitinib Outperforms Deucravacitinib in Phase 3 Head-to-Head Psoriasis Trialhttps://reachmd.com/news/zasocitinib-outperforms-deucravacitinib-in-phase-3-head-to-head-psoriasis-trial/2488633/Investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) demonstrated superior skin clearance compared with deucravacitinib in adults with moderate-to-severe plaque psoriasis, according to phase 3 data presented at the European Academy of Dermatology & Venereology (EADV)
- SEV Laser Becomes SEV SKIN Amid Rising Demand for Aesthetic Treatmentshttps://reachmd.com/news/sev-laser-becomes-sev-skin-amid-rising-demand-for-aesthetic-treatments/2488558/SEV Laser is rebranding as SEV SKIN, reflecting the med spa company’s expansion beyond laser hair removal into a broader range of aesthetic treatments, including skin services and injectables, according to a press announcement. The new identity comes 16 years after t
- Emblation Names Four Medical Affairs Advisors for SwiftProhttps://reachmd.com/news/emblation-names-four-medical-affairs-advisors-for-swiftpro/2488631/Emblation has appointed four clinicians and podiatry experts as Medical Affairs Advisors to support clinical education initiatives surrounding its SwiftPro microwave therapy system, which the company said recently received US Food and Drug Administration (FDA) 510(k) cleara
- Acrotech Brings Difamilast 1% Ointment for Atopic Dermatitis to UShttps://reachmd.com/news/acrotech-brings-difamilast-1-ointment-for-atopic-dermatitis-to-us/2488630/Acrotech Biopharma Inc. announced the United States launch of ADQUEY (difamilast 1%) ointment, a nonsteroidal topical treatment for mild-to-moderate atopic dermatitis (AD) in adults and pediatric patients aged 2 years and older. Difamilast was originally developed by Otsuka Pharmaceutical
- Low Proteinuria Linked to Fewer Events in Lupus Nephritishttps://reachmd.com/news/low-proteinuria-fewer-events-lupus-nephritis/2488627/Key Takeaways Among Japanese patients with biopsy-confirmed class III/IV lupus nephritis, lower baseline proteinuria was associated with fewer kidney-failure-or-death events. Patients with lower proteinuria had better baseline kidney function and less histologic acti